A phase 2 trial
for children with
Pediatric Growth Hormone Deficiency
OraGrowtH Trials is a clinical trial program involving an oral investigational drug, called LUM-201, for Pediatric Growth Hormone Deficiency (PGHD). This investigational drug for PGHD is an oral tablet. It is different from the currently approved injections of recombinant human growth hormone (rhGH) for children with Growth Hormone Deficiency.
What is the OraGrowtH210 Trial?
OraGrowtH210 Trial is a research trial studying
LUM-201 as a potential oral treatment for Pediatric Growth Hormone Deficiency (PGHD) in pre-pubertal children.
OraGrowtH210 Trial is a Phase 2 randomized trial.
The sponsor of this research study is Lumos Pharma and it is currently enrolling patients.
What is the Purpose
of the Trial?
The purpose of the OraGrowtH210 Trial is to study the investigational drug in PGHD by:
Assessing different daily oral dosages to find an optimal dose of LUM-201. Some children will be randomly assigned to the current standard of care (rhGH injections)
Observing safety and tolerability
Who Can Participate?
Pre-pubertal children, ages 3-12, diagnosed with PGHD, but have not started any Growth Hormone treatment, are invited to screen for trial eligibility.
If your child is eligible for the OraGrowtH210 Trial, the study will last for about 6 months and there will be clinic visits required.
The randomized trial will be open to 80 participants and the clinical sites are planned in the United States and other countries.
About the Sponsor
Lumos Pharma is passionately focused on developing therapeutics for rare diseases.
Rare disease patients and their caretakers inspire us to learn as much as we can to persevere and continue to advance the development of potential therapies to treat rare diseases. We are honored to work on collaborative projects such as increasing disease awareness, enabling better diagnostic modalities and access, and providing education and services to support patient and healthcare communities.
We are connected globally and proudly based in Austin, Texas and Ames, Iowa.